Trial Profile
Biweekly Versus Triweekly Raltitrexed With Oxaliplatin (With or Without Bevacizumab) in First-line Metastatic Colorectal Cancer (EROS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Aug 2020
Price :
$35
*
At a glance
- Drugs Oxaliplatin (Primary) ; Raltitrexed (Primary) ; Bevacizumab
- Indications Colorectal cancer
- Focus Pharmacokinetics
- Acronyms EROS
- 12 Aug 2020 Results assessing exposure-response analysis of Raltitrexed assessing liver toxicity published in the British Journal of Clinical Pharmacology
- 13 Jul 2016 New trial record